➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: July 25, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,153,964

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,153,964 protect, and when does it expire?

Patent 7,153,964 protects ZYKADIA and is included in two NDAs.

This patent has twenty-six patent family members in twenty countries.

Summary for Patent: 7,153,964
Title:Pyrimidine compounds
Abstract: Pyrimidine derivatives of formula (I) wherein: Qh.sub.1 and Q.sub.2 are independently selected from aryl or carbon linked heteroaryl optionally substituted as defined within; and one of Q.sub.1 and Q.sub.2 or both Q.sub.1 and Q.sub.2 is substituted on a ring carbon by one group selected from sulphamoyl, N--(C.sub.1-4alkyl)sulphamoyl (optionally substituted by halo or hydroxy), N,N-di-(C.sub.1-4alkyl)sulphamoyl (optionally substituted by halo or hydroxy), C.sub.1-4alkylsulphonyl (optionally substituted by halo or hydroxy) or a substituent of the formula (Ia) or (Ia'): wherein Q.sub.1, Q.sub.2, G, R.sup.1, Y, Z, Q.sub.3, n and m are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) inhibitors are also described ##STR00001##
Inventor(s): Pease; Elizabeth Janet (Macclesfield, GB), Breault; Gloria Anne (Macclesfield, GB), Morris; Jeffrey James (Macclesfield, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/220,139
Patent Claim Types:
see list of patent claims
Compound; Process; Composition;

Drugs Protected by US Patent 7,153,964

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Novartis ZYKADIA ceritinib TABLET;ORAL 211225-001 Mar 18, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,153,964

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004888.4Mar 1, 2000
PCT Information
PCT FiledFebruary 26, 2001PCT Application Number:PCT/GB01/00782
PCT Publication Date:September 07, 2001PCT Publication Number: WO01/64654

International Family Members for US Patent 7,153,964

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 361916 ⤷  Try it Free
Australia 3395301 ⤷  Try it Free
Australia 765151 ⤷  Try it Free
Brazil 0108841 ⤷  Try it Free
Brazil PI0108841 ⤷  Try it Free
Canada 2399196 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.